Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® ...

Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate ...

The objective response rate was 70%, with 45% of patients achieving a complete response or better. The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic ™ (linvoseltamab ...

Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily ...

Rashmi Chugh, MD, discusses the outcomes and goals of a promising study for ozekibart plus chemotherapy in patients with ...

ORLANDO, Fla. — Adding epcoritamab (Epkinly) to the standard-of-care (SOC) therapy of lenalidomide (Revlimid) and rituximab (Rituxan), a combination known as R 2, lowered the risk for disease ...

A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...

Patients with large B-cell lymphoma (LBCL) who had stable or progressive disease at the end of treatment or relapsed within 3 months had markedly worse response rates and survival outcomes than those ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio ...